Results 101 to 110 of about 5,034 (114)

Transient negativity for the anti-TIF1γ antibody before treatment in juvenile dermatomyositis. [PDF]

Rheumatol Adv Pract
Fujita Y, Matsushita T, Sato M, Yoshihara S.   +3 more
europepmc   +1 more source

The emerging role of growth differentiation factor 15 as a potential disease biomarker in juvenile dermatomyositis. [PDF]

Rheumatology (Oxford)
Duvvuri B, Gonzalez-Chapa JA, Pachman LM, Morgan GA, Naik N, Shenoi S, Lood C.   +6 more
europepmc   +1 more source

[Relationship between common myositis-specific antibodies and clinical features in children with juvenile dermatomyositis]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Cheng SY, Lu JM, Li F.
europepmc   +1 more source

Exploring the clinical profiles and management of juvenile dermatomyositis in Africa: a survey of African rheumatology care providers. [PDF]

Pediatr Rheumatol Online J
Perfetto J, Lewandowski LB, Wahezi DM, Ogega V, Ahimbisibwe J, Webb K, Scott C, Migowa A.   +7 more
europepmc   +1 more source

Juvenile dermatomyositis in Western Switzerland

Pediatric Rheumatology Online Journal, 2011
Hofer M, Enders F
doaj   +1 more source

Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons. [PDF]

Expert Opin Pharmacother
Wallwork RS, Paik JJ, Kim H.
europepmc   +1 more source

Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis. [PDF]

Rheumatology (Oxford)
Papadopoulou C, Martin N, Rafiq N, McCann L, Varner G, Nott K, Compeyrot-Lacassagne S, Leandro M, Foley C, Warrier K, Green N, Wan M, Dehbi HM, Whitehead J, Eleftheriou D, Brogan P.   +15 more
europepmc   +1 more source

Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype. [PDF]

JCI Insight
Turnier JL, Vandenbergen SM, McClune ME, Goudsmit C, Matossian S, Riebschleger M, Saad N, Madison JA, Mohan S, Gudjonsson JE, Tsoi LC, Berthier CC, Kahlenberg JM.   +12 more
europepmc   +1 more source